Aren Karapetyan, Oncology Resident at Yerevan State Medical University named after Mkhitar Heratsi, shared a post on LinkedIn:
“The PLATO ACT 4 trial demonstrates significant clinical benefits from reducing the IMRT dose in the treatment of anal cancer, marking a major step forward in optimizing anal cancer therapy.”
